NASDAQ$THRD
Third Harmonic Bio Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Announced financial results for the third quarter ended September 30, 2023.
Third Harmonic Bio reported a net loss of $7.3 million for the third quarter of 2023, with cash and cash equivalents totaling $273.9 million as of September 30, 2023. The company is on track to file a U.S. IND application for THB335 and initiate clinical studies in 1H'24.
- On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24.
- Cash and cash equivalents totaled $273.9 million as of September 30, 2023.
- Research and development (R&D) expenses increased to $6.0 million for the three months ended September 30, 2023.
- Net loss for the three months ended September 30, 2023 decreased to $7.3 million.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$0
Forward guidance
Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro